About Alchemab Therapeutics

Alchemab discovers naturally protective antibodies by studying resilient individuals who overcome or resist hard to treat diseases such as cancer and neurodegenerative conditions. The company sequences millions of antibodies from long term survivors and people with slow progressing disorders, using computational tools and deep learning to identify convergent protective antibodies across these resilient populations. The antibodies are developed into therapeutics for broader patient populations who lack this natural protective response. By mining the immune system's own solutions rather than designing treatments from scratch, Alchemab creates disease modifying therapies for conditions that remain difficult to treat.